ANNX late-stage GBS and GA programs advancing; US, Europe filings due soon
Late-stage programs in GBS and GA are advancing, with clinical efficacy and trial design described as robust. Regulatory filings in the US and Europe are expected soon, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.